Loading...

AXSM AXSOME THERAPEUTICS INC US FDA Inspections 8-K Filing

XSM

XSM

AXSOME THERAPEUTICS INC

(AXSM)

2025 8-K

PDE10A Acquisition

Financial Results Update

Patent Settlement

Preliminary Revenue Update

FDA Review Acceptance

Financial Update

FDA Generic Notice

Financial Statements

New Product Launches

New Product Launches

Settlement Agreement

Equity Offerings

Financial Statements

Patent Settlement

FDA Meeting Support

Financial Results

Patent Settlement

Financial Results

Loan Agreement Amendment

FDA Acknowledgment

Patent Litigation Dismissed

Earnings Report

Annual Meeting of Stockholders

Patent Litigation Settlement

Financial Results Announcement

Results of CRESCENDO survey...

Phase 3 Trial Initiation

Update of Corporate Present...

Financial Results Announcement

Financial Update

Investor Day Event

Financial Results Announcement

Appointment of Director

Earnings Report

Notice Letter for Generic V...

Sale of Common Stock

Underwriting Agreement

Appointment of New Independ...

Annual Meeting Approval of ...

Financial Results Announcement

Reaffirmation of Cash Flow ...

Earnings Reports

License Agreement with Atna...

Notice Letter for Generic V...

Loan Agreement Amendment

External Links:

On December 31, 2025, Axsome Therapeutics, Inc. announced that the FDA accepted its application for Priority Review concerning a treatment for Alzheimer's Disease Agitation, and received meeting minutes for its upcoming NDA for AXS-12 for narcolepsy.

AI Assistant

AXSOME THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.